Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Magainin Pharm (MAGN) -- Ignore unavailable to you. Want to Upgrade?

To: Dave K who wrote (161)	1/8/1999 7:43:00 AM
From: Shlepper	Read Replies (1) \| Respond to of 233

Victor, Dave: The appointment of a director of manufacturing demonstrates confidence both in a product approval, and in a cheaper process than farming out to Abbott. The news out on the asthma genomes is good news in that the long term outlook with strong pipeline in other critical health area is apparent. Next news out will be on the results of the squalamine clinical trials. This should give us all a boost, and momentum through to the summer where the approval of Cytolex will make Magainin a hot stock. This is our year, and just in time - I've got lots of college tuition expenses to pay. Good Luck! Shep